Regeneron (REGN) exec says it expects to price obesity drug reasonably close to parity with therapies that do not offer cholesterol lowering benefits, according to remarks at a TD Cowen conference
Importance
Level 1
- Co is actively looking at acquisition opportunities.
#REGENERON PHARMACEUTICALS INC#REGN.US#COWEN GROUP INC#EQUITIES#EU SESSION#US SESSION#PARITY#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#REGN#US EQUITIES